Dr Anne Mackie, Director of PHE Screening, explains how inequalities affect screening and what actions we are taking to understand and address these differences.
Dr Anne Mackie
Dr Anne Mackie is the Director of Programmes for the UK National Screening Committee.
Anne has worked in Public Health for nearly 20 years across London and the South East. Previous roles have included medical director of the National Specialist Commissioning Advisory Group, Director of Public Health in Kent and Director of Public Health in South West London. Latterly Anne was Director of Public Health for London SHA before taking on her current post in August 2007. She lives in London with her partner and their daughter.
The annual call is your opportunity to make a proposal for a new topic to be considered by the UK NSC as part of its regular review process.
I’m delighted to report that following the sterling work of our child vision group, we are now consulting on all the draft resources they have produced.
Some of us in Public Health England (PHE), myself included, have worked in screening a long time.
In the short video below, Dr Anne Mackie, Director of Screening for Public Health England, reflects on screening's achievements during 2016.
Group B Streptococcus (GBS) is an important cause of illness in babies, children and elderly adults. It remains the commonest infection that causes serious illness in newborn babies.
A new test will be added to the fetal anomaly screening pathway following an announcement by the Department of Health.
Children have all sorts of eye problems (just like adults) from viral conjunctivitis through to mild or moderate sight problems and, very rarely, blindness. Most children with eye problems are picked up by their parents or teachers.
The UK National Screening Committee (UK NSC) has more than 400 registered stakeholders and many other groups interested in its work. A number of these will be keen to see population screening introduced in the UK for a condition that …
The NHS Cervical Screening Programme in England relies on laboratories to screen and report on cervical cytology samples (3.2 million were examined in 2014-15).